120 related articles for article (PubMed ID: 16520661)
1. Anti-proliferative effect of peroxisome proliferator-activated receptor gamma agonists on human malignant melanoma cells in vitro.
Freudlsperger C; Moll I; Schumacher U; Thies A
Anticancer Drugs; 2006 Mar; 17(3):325-32. PubMed ID: 16520661
[TBL] [Abstract][Full Text] [Related]
2. Ligands for the peroxisome proliferator-activated receptor-gamma have inhibitory effects on growth of human neuroblastoma cells in vitro.
Valentiner U; Carlsson M; Erttmann R; Hildebrandt H; Schumacher U
Toxicology; 2005 Sep; 213(1-2):157-68. PubMed ID: 16009482
[TBL] [Abstract][Full Text] [Related]
3. Mistletoe lectin-I augments antiproliferative effects of the PPARgamma agonist rosiglitazone on human malignant melanoma cells.
Freudlsperger C; Dahl A; Hoffmann J; Reinert S; Schumacher U
Phytother Res; 2010 Sep; 24(9):1354-8. PubMed ID: 20812278
[TBL] [Abstract][Full Text] [Related]
4. [Effects of peroxisome proliferator-activated receptor-gamma ligand troglitazone on colon cancer cell growth].
Koirala K; Wan YL; Liu YC; Wang X; Cui W; Wang CL; Chen HN; Wang HY; Zhu J
Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Aug; 38(4):385-8. PubMed ID: 16892143
[TBL] [Abstract][Full Text] [Related]
5. Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor γ-independent mechanism.
Lützen U; Zhao Y; Lucht K; Zuhayra M; Marx M; Cascorbi I; Culman J
Naunyn Schmiedebergs Arch Pharmacol; 2017 Jan; 390(1):37-48. PubMed ID: 27664035
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
7. The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells.
Freudlsperger C; Thies A; Pfüller U; Schumacher U
Anticancer Res; 2007; 27(1A):207-13. PubMed ID: 17352234
[TBL] [Abstract][Full Text] [Related]
8. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma.
Eucker J; Sterz J; Krebbel H; Zavrski I; Kaiser M; Zang C; Heider U; Jakob C; Elstner E; Sezer O
Anticancer Drugs; 2006 Aug; 17(7):763-9. PubMed ID: 16926626
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo anti-melanoma effects of ciglitazone.
Botton T; Puissant A; Bahadoran P; Annicotte JS; Fajas L; Ortonne JP; Gozzerino G; Zamoum T; Tartare-Deckert S; Bertolotto C; Ballotti R; Rocchi S
J Invest Dermatol; 2009 May; 129(5):1208-18. PubMed ID: 19177142
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activating receptors: a new way to treat melanoma?
Schadendorf D
J Invest Dermatol; 2009 May; 129(5):1061-3. PubMed ID: 19369932
[TBL] [Abstract][Full Text] [Related]
12. PPARgamma agonists attenuate proliferation and modulate Wnt/beta-catenin signalling in melanoma cells.
Smith AG; Beaumont KA; Smit DJ; Thurber AE; Cook AL; Boyle GM; Parsons PG; Sturm RA; Muscat GE
Int J Biochem Cell Biol; 2009 Apr; 41(4):844-52. PubMed ID: 18822385
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor-gamma agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines.
Yang YC; Tsao YP; Ho TC; Choung IP
Int J Gynecol Cancer; 2007; 17(2):418-25. PubMed ID: 17316361
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers.
Xin B; Yokoyama Y; Shigeto T; Futagami M; Mizunuma H
Cancer; 2007 Aug; 110(4):791-800. PubMed ID: 17582802
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines.
Burton JD; Castillo ME; Goldenberg DM; Blumenthal RD
Anticancer Drugs; 2007 Jun; 18(5):525-34. PubMed ID: 17414621
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of ERK activity enhances the cytotoxic effect of peroxisome proliferator-activated receptor γ (PPARγ) agonists in HeLa cells.
Chang HK; Kim DS; Chae JJ; Kim M; Myong JP; Lee KH; Lee MW; Park TC
Biochem Biophys Res Commun; 2017 Jan; 482(4):843-848. PubMed ID: 27888104
[TBL] [Abstract][Full Text] [Related]
17. The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells.
Shim J; Kim BH; Kim YI; Kim KY; Hwangbo Y; Jang JY; Dong SH; Kim HJ; Chang YW; Chang R
Int J Oncol; 2010 Jan; 36(1):223-31. PubMed ID: 19956851
[TBL] [Abstract][Full Text] [Related]
18. Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma.
Mössner R; Schulz U; Krüger U; Middel P; Schinner S; Füzesi L; Neumann C; Reich K
J Invest Dermatol; 2002 Sep; 119(3):576-82. PubMed ID: 12230498
[TBL] [Abstract][Full Text] [Related]
19. Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).
Takenokuchi M; Saigo K; Nakamachi Y; Kawano S; Hashimoto M; Fujioka T; Koizumi T; Tatsumi E; Kumagai S
Acta Haematol; 2006; 116(1):30-40. PubMed ID: 16809887
[TBL] [Abstract][Full Text] [Related]
20. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.
Lecomte J; Flament S; Salamone S; Boisbrun M; Mazerbourg S; Chapleur Y; Grillier-Vuissoz I
Breast Cancer Res Treat; 2008 Dec; 112(3):437-51. PubMed ID: 18204896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
